---
layout: default
title: Apis Mellifera Araneus Diadematus Arnica Montana A
parent: 僅模型預測 (L5)
nav_order: 347
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Araneus Diadematus Arnica Montana A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Compound (Venom-Botanical Complex, 26 Components): No Original Indication or Repurposing Prediction Available

## One-Sentence Summary

This product is a complex homeopathic formulation containing 26 active ingredients, including animal venoms, insect-derived substances, botanical extracts, and mineral compounds (including Arsenic Trioxide).
**No TxGNN repurposing prediction was generated** for this compound because no DrugBank ID could be mapped and no original regulatory indication is on record.
Without these two anchor points, a drug repurposing analysis cannot be meaningfully conducted at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no Taiwan regulatory approval on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline produced no prediction |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Approvals | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This formulation consists of 26 homeopathic components spanning three biological categories:

**Animal venoms and insect-derived substances (9 ingredients):** Apis mellifera (honeybee), Araneus diadematus (garden spider), Formica rufa (red ant), Lachesis muta venom (bushmaster snake), Latrodectus mactans (black widow spider), Lycosa tarantula (wolf spider), Pulex irritans (human flea), Theridion curassavicum (orange spider), and Vespa crabro (European hornet).

**Botanical and plant-derived substances (15 ingredients):** Arnica montana, Azadirachta indica bark (neem), Bryonia alba root, Calendula officinalis, Daphne mezereum bark, Dieffenbachia seguine, Echinacea, Grindelia hirsutula, Hamamelis virginiana (witch hazel), Hypericum perforatum (St. John's Wort), Ledum palustre, Rancid beef, Solidago virgaurea (goldenrod), Strychnos nux-vomica seed, Thuja occidentalis, and Toxicodendron pubescens leaf.

**Inorganic and mineral compounds (1 ingredient):** Arsenic trioxide.

The TxGNN pipeline requires a unique **DrugBank ID** to anchor a compound within the biomedical knowledge graph. Because this product is a multi-ingredient homeopathic preparation, no single DrugBank ID was assignable to the formulation as a whole — the DrugBank query returned a result count of 1 but mapped to no valid `drugbank_id`. As a result, both the Knowledge Graph (KG) and Deep Learning (DL) prediction steps returned zero candidates, and `predicted_indications` is empty.

Furthermore, no original approved indication exists in the Taiwan regulatory database (0 licenses, market status: 未上市), which removes the second anchor point required for a "From Indication A → Indication B" repurposing hypothesis.

---

## Taiwan Market Information

No regulatory licenses found for this formulation. This compound is not currently marketed in Taiwan under any recorded authorization.

---

## Safety Considerations

No safety data (warnings, contraindications, or drug-drug interactions) was retrievable from any data source queried on 2026-03-24. Please refer to the product's package insert or manufacturer's monograph for safety information.

> **Important note on Arsenic Trioxide:** One of the 26 listed ingredients — Arsenic Trioxide — is also the active pharmaceutical ingredient in **Trisenox®**, a conventional antineoplastic agent approved for acute promyelocytic leukemia (APL). If Arsenic Trioxide in this formulation is present at **pharmacologically active concentrations** (rather than ultra-dilute homeopathic concentrations), its antineoplastic safety profile — including QT prolongation risk, APL differentiation syndrome, myelosuppression, and hepatotoxicity — applies and must be separately evaluated against Trisenox® prescribing information before any repurposing analysis proceeds.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate cannot be evaluated because no DrugBank mapping, no Taiwan regulatory approval, and no TxGNN prediction exist for this 26-ingredient homeopathic formulation. Proceeding without resolving these fundamental data gaps would produce unreliable results.

**To proceed, the following is needed:**

- **Confirm product identity:** Identify the brand name and manufacturer to determine if this formulation is registered as a homeopathic product in any jurisdiction (e.g., FDA OTC monograph, EMA, Health Canada) and obtain the corresponding product monograph.
- **Clarify Arsenic Trioxide concentration:** Determine whether Arsenic Trioxide is present at homeopathic dilution (e.g., 6C, 30C — pharmacologically inert) or at a measurable active dose. This determines whether antineoplastic safety regulations apply.
- **Re-submit single active ingredient if applicable:** If the intended focus is a single key ingredient (e.g., Arsenic Trioxide, Hypericum perforatum, or Echinacea), re-submit that individual compound to the TxGNN pipeline with its proper DrugBank ID for a valid repurposing analysis.
- **Resolve Data Gap DG001:** Download the package insert PDF from the TFDA website and parse warning/contraindication text.
- **Resolve Data Gap DG002:** Perform individual DrugBank API lookups for each of the 26 component ingredients to establish MOA profiles for mechanistic analysis.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

